An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will announce its fourth quarter and year-end 2022 financial results on March 8, 2023, after U.S. markets close. Following this announcement, management will host a conference call and live webcast at 4:30 p.m. ET to discuss the results, including a Q&A session. Participants can join the call via phone or the company's Investor Relations website. A replay of the call will be available afterward. Evolus focuses on the aesthetic neurotoxin market and aims to evolve beauty consumer experiences with innovative products like Jeuveau®, its flagship offering.
Positive
None.
Negative
None.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its fourth quarter and year end 2022 financial results and provide a business update on Wednesday, March 8, 2023, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13736592. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.
Jeuveau® is a registered trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
What date will Evolus release its Q4 2022 financial results?
Evolus will release its Q4 2022 financial results on March 8, 2023.
What time is the Evolus conference call scheduled?
The Evolus conference call is scheduled for 4:30 p.m. ET on March 8, 2023.
How can I participate in the Evolus financial results call?
You can participate by dialing (877) 407-6184 for U.S. calls or (201) 389-0877 for international calls, or by joining the live webcast on the Evolus Investor Relations page.
Where can I find the archived replay of the Evolus conference call?
The archived replay of the Evolus conference call will be available on their Investor Relations webpage after the call.
What is Evolus known for in the beauty market?
Evolus is known for its flagship product Jeuveau®, a neurotoxin dedicated exclusively to aesthetics.
